Siemens Healthineers Investors Face a Long Wait as Spin-Off Pushed Back to 2027

Siemens Healthineers shares plunge to €35.43 as spin-off delayed to 2027, diagnostics drag in China, and tariffs add €400M burden; analysts still see 70% upside.

The market has delivered a stark verdict on Siemens Healthineers. Shares tumbled to a 52-week low of €35.43 in Xetra trading on Tuesday, extending the year-to-date decline to roughly 20 percent. The stock now sits a world away from its summer peak near €50, with two distinct headwinds converging to keep the pressure on.

A Delayed Break from the Parent

The most immediate source of disappointment is the revised timeline for the company's separation from Siemens AG. Rather than completing the spin-off in 2026 as many investors had anticipated, the parent group now intends to put the proposal to a shareholder vote at its annual general meeting in February 2027. Under the direct spin-off plan, around 30 percent of Healthineers shares would be distributed to Siemens shareholders, with the industrial conglomerate ultimately aiming to reduce its current 67 percent stake to below one-fifth. That remaining holding would be classified as a financial investment.

The postponement strips the stock of a near-term catalyst that had been supporting valuations. With the regulatory picture still incomplete, the market has little choice but to look past the structural story and focus on the operational reality.

Diagnostics Drag and China Weakness

That reality is proving uncomfortable. The Laboratory Diagnostics division remains the primary operational headache, with the Chinese market particularly problematic. An anti-corruption campaign has centralised procurement processes, hitting sales in what was once a growth engine. The segment posted a slight revenue decline in the most recent period, and management is responding by streamlining the portfolio — launching new tests this year while phasing out older systems.

The numbers tell the story. First-quarter revenue rose 3.8 percent, but adjusted earnings per share slipped to €0.49, a 3 percent decline. For the current second quarter, analysts expect EPS to fall further to €0.51, down from €0.56 a year earlier, with revenue stagnating at roughly €5.9 billion.

Tariffs and Currency Add to the Burden

The full-year outlook is under additional pressure from external factors. Management has flagged a tariff burden of around €400 million, alongside negative currency effects of €200 million to €250 million. Adjusted earnings per share for fiscal 2026 are forecast to land between €2.20 and €2.40, compared with €2.39 last year.

A Solvency Bright Spot

Not everything is bleak. Moody's recently assigned an A3 rating to Siemens Healthineers, signalling a solid foundation for independent capital market financing once the spin-off is complete. That financial standing provides some reassurance that the company can fund its own growth without relying on the parent.

Analyst Optimism vs Market Reality

The analyst community remains broadly bullish despite the share price rout. The average price target stands at €53.06, with Jefferies recommending a buy and a target of €60 — implying upside of nearly 70 percent from current levels. A projected dividend of €1.01 for the current year offers additional support to the valuation case.

Technically, the relative strength index sits at 31.6, indicating an oversold condition. Whether that proves sufficient to trigger a stabilisation depends heavily on the second-quarter results due on 7 May. That report gives management a platform to demonstrate tangible progress in restructuring the China business and to show how deeply the headwinds from both China and the US are cutting into earnings.

For now, investors are left weighing a distant structural prize against immediate operational pain. The next few weeks will determine which narrative gains the upper hand.